Franziska Wittmann

Dr. Franziska Wittmann

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2020 in ASAIO Journal
Verified
Journal Article
Closed access
JRJulia Riebandt
Julia Riebandt
TSThomas Schlöglhofer
Thomas Schlöglhofer
RMRoxana Moayedifar
Roxana Moayedifar
Dominik WiedemannDominik Wiedemann
Dominik Wiedemann
FWFranziska Wittmann
Franziska Wittmann
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer
Despite increasing popularity and multiple postulated benefits, less invasive (LIS) left ventricular assist device (LVAD) implantation has not been sufficiently compared with standard full sternotomy (FS). We report the outcomes of a propensity score analysis designed to compare LIS and FS LVAD implantation, with perioperative blood product use, adverse event rates, and mortality as primary objective. From September 2010 to August 2016, 159 consecutive patients received a Medtronic HVAD or Abbott HeartMate 3 LVAD via a FS or LIS approach. Outcomes were analyzed using proportional hazard Cox regression, with risk adjustment based on a LIS approach propensity score model computed from demographics, risk factors, and operative covariates. Seventy-five patients were matched and compared (HVAD 83% [n = 62]; LIS approach 43% [n = 32]; mean age 60 ± 12 years; 89% [n = 67] male; 48% [n = 36] ischemic cardiomyopathy [ICMP]; 37% [n = 28]). Patient groups were comparable with regard to preoperative patient characteristics. Less invasive LVAD implantation was successful in all patients with no intraoperative conversions. In-hospital mortality was 16% in both groups, despite 37% Interagency Registry for Mechanically Assisted Circulatory Support Level I patients. Overall, 28% of the LIS patients did not receive any blood products intraoperatively, whereas, in the FS group, only two patients (5%) did not require the administration of blood products (p = 0.000). This was also a significant finding in the overall perioperative phase in which seven LIS patients (22%) who not receive any blood products versus two FS patients (5%; p = 0.033). Otherwise, outcomes were comparable. Less invasive LVAD implantation is a feasible, safe, and reduces blood product use.

5 September 2021 in Life
Verified
Journal Article
Open access
PDF file
FWFranziska Wittmann
Franziska Wittmann
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
JRJulia Riebandt
Julia Riebandt
ASAnne-Kristin Schaefer
Anne-Kristin Schaefer
Dominik WiedemannDominik Wiedemann
Dominik Wiedemann
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer
Several risk scores and classifications are available to predict peri- and post-operative mortality of patients with end stage heart failure receiving Left Ventricular Assist Device (LVAD) therapy. Sarcopenia has been suggested as a sensitive predictor for post-operative mortality. We evaluated whether the psoas muscle area can predict mortality in patients undergoing LVAD implantation. The indexed psoas mean area (PMAi) was obtained by measuring the psoas muscle area at the superior endplate of the third lumbar vertebra correlated to body surface area of 106 adult patients undergoing LVAD implantation (Medtronic HVAD n = 41, Abbott HeartMate II n = 4, Abbott HeartMate 3 n = 61; mean age 65, IQR 12, 90.6% male; INTERMACS Level 1 24.5%; ischemic CMP 64.2%). Patients were divided in two groups: high/moderate and low muscle mass. The primary endpoint was 30-day mortality, assessed using a multivariate Cox proportional hazards model. Baseline characteristics did not differ between patients with high or moderate and low PMAi. Estimated survival calculated a significant higher 30-day mortality in patients with low PMAi (p = 0.04). Multivariable Cox proportional hazards regression analysis indicated low PMAi, history of previous cardiac surgery and levels of bilirubin as independent predictors of mortality in the first 30 days. In conclusion, indexed psoas muscle area predicts mortality after LVAD implantation and can be used as an additional tool for risk stratification.

20 March 2022 in Life
Verified
Journal Article
Open access
PDF file
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
FWFranziska Wittmann
Franziska Wittmann
RPRobert Paus
Robert Paus
JRJulia Riebandt
Julia Riebandt
ASAnne-Kristin Schaefer
Anne-Kristin Schaefer
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer
Right heart failure (RHF) is a severe complication after left ventricular assist device (LVAD) implantation. The aim of this study was to analyze the incidence, risk factors, and biomarkers for late RHF including the possible superiority of the device and implantation method. This retrospective, single-center study included patients who underwent LVAD implantation between 2014 and 2018. Primary outcome was freedom from RHF over one-year after LVAD implantation; secondary outcomes included pre- and postoperative risk factors and biomarkers for RHF. Of the 145 consecutive patients (HeartMate 3/HVAD: n = 70/75; female: 13.8%), thirty-one patients (21.4%) suffered RHF after a mean LVAD support of median (IQR) 105 (118) days. LVAD implantation method (less invasive: 46.7% vs. 35.1%, p = 0.29) did not differ significantly in patients with or without RHF, whereas the incidence of RHF was lower in HeartMate 3 vs. HVAD patients (12.9% vs. 29.3%, p = 0.016). Multivariate Cox proportional hazard analysis identified HVAD (HR 4.61, 95% CI 1.12–18.98; p = 0.03), early post-op heart rate (HR 0.96, 95% CI 0.93–0.99; p = 0.02), and central venous pressure (CVP) (HR 1.21, 95% CI 1.05–1.39; p = 0.01) as independent risk factors for RHF, but no association of RHF with increased all-cause mortality (HR 1.00, 95% CI 0.99–1.01; p = 0.50) was found. To conclude, HVAD use, lower heart rate, and higher CVP early post-op were independent risk factors for RHF following LVAD implantation.

15 April 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MTMaximilian Tscharre
Maximilian Tscharre
FWFranziska Wittmann
Franziska Wittmann
DKDaniela Kitzmantl
Daniela Kitzmantl
SLSilvia Lee
Silvia Lee
BEBeate Eichelberger
Beate Eichelberger
TGThomas Gremmel
Thomas Gremmel
Growth differentiation factor (GDF)-15 inhibits platelet activation, prevents thrombus formation, and has been linked to bleeding events. This was a prospective study including 51 left-ventricular assist device (LVAD) patients on aspirin and phenprocoumon. Platelet surface expression of activated glycoprotein (GP) IIb/IIIa was assessed by flow cytometry, and platelet aggregation was measured by multiple electrode aggregometry (MEA) in response to arachidonic acid (AA), adenosine diphosphate (ADP), and thrombin receptor-activating peptide (TRAP), a protease-activated-receptor-1 (PAR-1) agonist. GDF-15 was determined with a commercially-available assay. There was a trend towards an inverse correlation of GDF-15 with activated GPIIb/IIIa in response to TRAP (r = −0.275, p = 0.0532) but not in response to AA and ADP. Moreover, GDF-15 correlated with MEA TRAP (r = −0.326, p = 0.0194), whereas it did not correlate with MEA ADP and MEA AA. In a second step, GDF-15 levels in the fourth quartile were defined as high GDF-15. Patients with high GDF-15 showed significantly lower TRAP-inducible platelet aggregation by MEA compared to patients in the first quartile (63 AU vs. 113 AU, p = 0.0065). In conclusion, in LVAD patients receiving state-of-the-art antithrombotic therapy, GDF-15 correlates inversely with residual platelet reactivity via PAR-1.

23 April 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AAArezu Aliabadi-Zuckermann
Arezu Aliabadi-Zuckermann
EOEmilio Osorio-Jaramillo
Emilio Osorio-Jaramillo
CKChristoph Knosalla
Christoph Knosalla
JGJan Gummert
Jan Gummert
GSGabor Szabo
Gabor Szabo
AZAndreas Zuckermann
Andreas Zuckermann

Verified
Journal Article
Open access
PDF file
FWFranziska Wittmann
Franziska Wittmann
CNClemens Nebert
Clemens Nebert
TRTeresa Ruthmeier
Teresa Ruthmeier
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer
Barbara MessnerBarbara Messner
Barbara Messner
The detrimental effect of cigarette smoking has become undeniable, based on decades of research. Twenty years ago, the electronic cigarette was introduced to the market and has since then been presented as the alleged healthy alternative. Clever marketing by the industry has led to a global rise in the number of users, especially adolescents and young adults. Clinicians and scholars have praised the electronic cigarette as a tool for tobacco smoke cessation, hoping for a reduction in burden on healthcare systems. Yet accumulating evidence suggests otherwise. Over the years, several in vitro and in vivo studies in animal models and humans have shown electronic cigarettes to be associated with pulmonary, cancerous and cardiovascular diseases. This review revisits the so-far available clinical evidence concerning cardiovascular diseases and discusses research gaps that still need to be addressed, specifically focusing on patients undergoing cardiac surgery.